Evaluation of External Assets for In-licensing
First written in FY2023-Q3. 7 of 13 entries say "Advanced", first in FY2023. Latest entry: FY2027-H1.
0 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「The Company continued examining potential indications for novel stable analogues of the bioactive lipid resolvin, which it in-licensed from Hokkaido University in November 2025, for multiple target diseases.」
The Company continued searching for and evaluating external programs and examining potential indications for novel stable resolvin analogues in-licensed from Hokkaido University in November 2025. - FY2026-H1RestatedAnnual report
「For external programs, the Company continued searching for and evaluating early-stage programs at academic and other research institutions and drug-discovery companies. In addition to TMS-010 described above, it continued evaluating from various perspectives another Hokkaido University seed under exclusive evaluation.」
The Company continues searching for and evaluating early-stage external programs and conducting exclusive evaluation of another Hokkaido University seed. - FY2025RestatedAnnual report
「For external programs, the Company continued searching for and evaluating early-stage programs at academic and other research institutions and drug-discovery companies. In addition to TMS-010 described above, it steadily evaluated from various perspectives another Hokkaido University seed under exclusive evaluation.」
The Company continues to search for and evaluate early-stage external programs and to evaluate Hokkaido University seeds other than TMS-010. - FY2025-H1RestatedAnnual report
「In addition to TMS-010 described above, the Company steadily evaluated from various perspectives another seed from Hokkaido University that is currently under exclusive evaluation.」
The Company continues evaluating another Hokkaido University seed in addition to TMS-010. - FY2025-Q1AdvancedAnnual report
「The Company steadily evaluated 2 seeds from Hokkaido University under exclusive evaluation. For 1 of them, which had been evaluated under an option agreement signed with the university in July 2022, the Company entered into a license agreement on 3 July 2024 after the end of the first quarter and acquired an exclusive worldwide license as TMS-010, a spinal cord injury drug candidate.」
The Company continued evaluating 2 Hokkaido University seeds and acquired an exclusive worldwide license for TMS-010 on 3 July 2024. - FY2024-Q3AdvancedAnnual report
「The drug candidate covered by the option agreement with Hokkaido University entered its second phase after completing the first phase of the exclusive evaluation period. The Company also entered into a three-party joint research agreement including Kanazawa University. For another project evaluated under an option agreement with the university since July 2022, evaluation was completed and discussions on the next step are continuing.」
The Hokkaido University candidate advanced from Phase 1 to Phase 2 of exclusive evaluation, and a three-party joint research agreement including Kanazawa University was signed. Discussions continue on the next step for another Hokkaido University project. - FY2024-Q2AdvancedAnnual report
「For external programs, the Company continued searching for and evaluating early-stage programs at academic and other research institutions and drug-discovery companies. On 8 May 2023, it entered into an option agreement with Hokkaido University for the exclusive evaluation and licensing of a drug candidate and began evaluating that candidate. It completed evaluation of a program for which it had entered into an option agreement with the university in July 2022 and is discussing the next steps based on the results.」
Evaluation began for a candidate under the Hokkaido University option agreement. For another Hokkaido University program, evaluation was completed and discussions on the next step began. - FY2024-Q1AdvancedAnnual report
「For external programs, the Company continued searching for and evaluating programs in the early research and development stages at academic and other research institutions and drug-discovery companies. On 8 May 2023, it entered into an option agreement with Hokkaido University for the exclusive evaluation and licensing of a drug candidate.」
The Company continued searching for and evaluating external programs and entered into an option agreement with Hokkaido University on 8 May 2023 for exclusive evaluation and licensing of a drug candidate. - FY2023AdvancedAnnual report
「In addition, the Company conducted a broad search of early-stage seeds from academia, research institutions and drug-discovery companies, and carried out focused evaluations of multiple candidates.」
The Company broadly searched early-stage programs from academia, research institutions and drug-discovery companies and advanced to focused evaluation of multiple candidates. - FY2023-Q3First statedAnnual report
「The Company is also considering the introduction of external assets and is collecting and evaluating experimental data.」
The Company is considering in-licensing external assets and is collecting and evaluating experimental data.